Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at risk of having one ...

Existing atherosclerotic cardiovascular disease (ASCVD) risk calculators appear to be inadequate, noted researchers led by ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Once-weekly semaglutide 2.4 mg reduced the risk for major adverse cardiovascular events among adults with overweight or obesity who were at risk for atherosclerotic cardiovascular disease, according ...

Discover Enlicitide, a new daily pill for genetic high cholesterol (HeFH). A recent trial shows it lowers bad LDL cholesterol ...

Objectives Heart failure (HF), chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) are highly prevalent conditions that often coexist. Using electronic health records (EHRs ...

NEW ORLEANS, LOUISIANA / ACCESS Newswire / November 12, 2025 / American Heart Association (“AHA”) Conference 2025, GENinCode ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment ...

Low-dose aspirin use of any frequency was associated with lower risk for myocardial infarction and ischemic stroke than nonuse.

Adding the PCSK9 inhibitor evolocumab to a high-intensity, cholesterol-lowering regimen reduced the risk of a first major ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...